{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Poolchanuan P"],"funding":["Mahidol University","National Research Council of Thailand","Wellcome Trust"],"pagination":["3408"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12835167"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["16(1)"],"pubmed_abstract":["The emergence of SARS-CoV-2 variants that evade immune responses poses challenges to effective prevention. We prospectively enrolled 111 COVID-19 patients in Thailand (2021-2022), who received homologous or heterologous vaccines or were unvaccinated. Plasma neutralizing antibody (nAb) levels against SARS-CoV-1 and 13 SARS-CoV-2 strains were measured using a multiplex surrogate virus neutralization test (sVNT) assay within a year. nAb levels increased in two weeks, showing strong inhibition against ancestral SARS-CoV-2 and non-omicron variants, but not against SAR-CoV-1 and lower responses to omicron variants. nAb levels declined by the day 60. Breakthrough patients with heterologous vaccines had higher nAb levels compared to other groups. nAb levels were lower in breakthrough patients with"],"journal":["Scientific reports"],"pubmed_title":["Longitudinal analysis of neutralizing antibodies against SARS-CoV-1 and different SARS-CoV-2 strains in breakthrough and unvaccinated COVID-19 patients in Thailand (2021-2022)."],"pmcid":["PMC12835167"],"funding_grant_id":["226120/Z/22/Z","220211"],"pubmed_authors":["Tayipto Y","Nguyet LA","Chantima W","Sette A","Stuart DI","Kronsteiner-Dobramysl B","SEACOVARIANTS","Iamsirithaworn S","Thanh VD","van Doorn HR","Chowplijit S","Tan CW","Abraham P","Wang LF","Supasa P","Piyaphanee W","Klenerman P","Hill J","Chantratita N","Boonprakob T","Screaton G","Selvaraj M","Dijokaite-Guraliuc A","Runcharoen C","Chantratita W","Luvira V","Tung TS","Grifoni A","Suwarti S","Hoang TC","Siripoon T","Yen LM","Chuapaknam V","Hoang VT","Simarmata E","Dien R","Boonthaworn K","Day NPJ","Han DDK","Das R","Dejnirattisai W","Hamers RL","Truc THC","Jones E","Hang VTT","Hemtong O","Phunpang R","Yap WC","Mongkolsapaya J","Nhu LNT","Kieu PT","Thwaites G","Lim BL","Hong NTT","Thanh LK","Thanh TT","Thwaites C","Poomchaichote T","Poolchanuan P","Ny NTH","Ngoc NM","Tiacharoen V","Anh NT","Zewdie M","Tan LV","Thao NT","Dulsuk A","Junpirom A","Thuy CT","Cheah PY","Shankar A","Dunachie S","Liu C","Chambers M"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal analysis of neutralizing antibodies against SARS-CoV-1 and different SARS-CoV-2 strains in breakthrough and unvaccinated COVID-19 patients in Thailand (2021-2022).","description":"The emergence of SARS-CoV-2 variants that evade immune responses poses challenges to effective prevention. We prospectively enrolled 111 COVID-19 patients in Thailand (2021-2022), who received homologous or heterologous vaccines or were unvaccinated. Plasma neutralizing antibody (nAb) levels against SARS-CoV-1 and 13 SARS-CoV-2 strains were measured using a multiplex surrogate virus neutralization test (sVNT) assay within a year. nAb levels increased in two weeks, showing strong inhibition against ancestral SARS-CoV-2 and non-omicron variants, but not against SAR-CoV-1 and lower responses to omicron variants. nAb levels declined by the day 60. Breakthrough patients with heterologous vaccines had higher nAb levels compared to other groups. nAb levels were lower in breakthrough patients with","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-12T10:19:25.258Z","creation":"2026-06-12T03:11:53.971Z"},"accession":"S-EPMC12835167","cross_references":{"pubmed":["41484240"],"doi":["10.1038/s41598-025-33388-7"]}}